Marc Beer is the CEO, Chairman, and Co-founder of Renovia. With over 25 years of development in diagnostics, devices, pharmaceuticals, and biotechnology.
Beer’s company Renovia is developing various therapeutic products to help solve pelvic floor issues that affect nearly 250 million women worldwide. The company’s first project: Leva, which is a Digital system that uses Bluetooth and visualization to allow women to rehabilitate and strengthen pelvic floor muscles, recently received FDA approval in April of 2018.
Beer attended Miami University from 1983 to 1987 in Oxford Ohio.
In 2000, Marc Beer became the CEO of ViaCell. Which is a company specializing in the collection and preservation of umbilical cord stem cells. Over the period of seven years, Marc Beer took the company ViaCell from its inception in 2000 to a rapidly growing operation. He also served at Erytech Pharma as a member of the board of directors, which is a bio-pharmaceutical company. Most recently, he held various positions at Genzyme as Vice President of Global Marketing.
More than 250 million women are affected by some sort of pelvic disorder worldwide, and this is what the company has set out to change. The company Renovia has already started to see success, with their first product Leva getting FDA approval in April.
Pelvic disorders often result in pain, pressure, and often times urinary incontinence, which also can result in pain during intercourse.
Fundraising done by and for Renovia included enough funds in order to run diagnostics, tests, and getting products FDA approval and commercialization of products. With his many years of experience in facilitating product approvals and commercial development in the biotech industry, many people believe that Marc Beer is the right person for this operation.
Marc Beer’s company Renovia, is organized and committed to women’s health products. Their goal is to provide a better quality of life for women who are affected by pelvic floor conditions.
The Longwood Fund, is an investing firm that is health-care focused. They invested early in Renovia, and joined the Series B Round. As well as numerous other contributors. The company has claimed that the funding will focus on using the funds mainly towards testing and developing for more and more diagnostic and therapeutic products, including another version of the Leva device. Learn more: https://www.slideshare.net/MarcBeer